SBIR/STTR Research Award

SBIR Phase II: A Gram-Negative Bacterial Secretion Platform for Cost-Effective, High-Purity Recombinant Protein Production

Award identifier 64b6f32d6805a666d789f2c123b4e109e6cade6c2776fd2881d6f5379d3e1fb5Awarding agency National Science Foundation

Award amount

$1,248,994

Program and phase

SBIR · Phase II

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
OPERA BIOSCIENCE, INC.
Proposal award date
2025-06-05
Contract end date
2027-05-31
UEI
GT5QNNN83TQ7
Solicitation number
NSF 24-580
Topic code
BT

Research abstract

The broader impact of this Small Business Innovation Research (SBIR) Phase II project will be felt at the societal, educational, and scientific levels. The cost and time saving potential of this protein secretion technology alone has the ability to better human health and speed new product development. The availability of lower cost manufacturing drugs that reach the market faster has the potential to save the United States a substantial amount of money going forward. A lower cost protein production strain that operates at scale would also support domestic supply chain resiliency and biosecurity. Reducing the cost of manufacturing biologic drugs would make it more economical to re-shore manufacturing of drugs and drug products to the United States from the current low-cost production countries that export to the United States. By manufacturing these drugs in the U.S., this technology could limit future supply chain disruptions caused by pandemics or complications to international trade. Reducing recombinant protein prices would also pave the way for biomanufactured alternatives in areas such as textiles and pave the way for new manufacturing processes in these industries. The proposed project will further develop an innovative bacterial protein secretion platform technology into a commercially viable, cost-effective protein expression platform capable of producing multiple classes of proteins at an industrial scale, while meeting commercial standards of activity and purity. While the platform is capable of generating limited revenue at pilot scale, achieving these Phase II milestones will allow for manufacturing of commercially relevant reagents at an economically feasible scale, while putting into place an industrially viable production and purification process. The proposed project will initially benchmark the capabilities of the platform by developing and optimizing industrial scale manufacturing processes for 3 different classes of proteins. This project wil

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

3 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $1,847,638. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: National Science Foundation, Department of Health and Human Services

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.